Ceribell, Inc.

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

VANCOUVER, BC, Dec. 12, 2025 /CNW/ -- USANewsGroup.com News Commentary – Point-of-care infectious disease diagnostics valued at $53 billion in 2024 are projected to nearly double by 2033, driven by AI systems that deliver laboratory-grade results at the bedside^[1]. Meanwhile, healthcare organizations implementing domain-specific AI tools surged 7x in 2025 as financial pressure mounts, with hospital expenses rising 6% annually while revenue grows just 3%^[2]. Five publicly traded companies are positioned at the center of this shift, each holding FDA clearance for AI systems that eliminate diagnostic delays and transform patient management at the point of care: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Heartflow, Inc. (NASDAQ: HTFL), CeriBell, Inc. (NASDAQ: CBLL), Medtronic plc (NYSE: MDT), and Abbott Laboratories (NYSE: ABT).

Industry analysts project AI could reduce healthcare spending by $200 billion to $360 billion annually through current technologies alone, with hospitals capturing $60 billion to $120 billion of those savings from improved clinical operations^[3]. The window for adoption is narrow, driven by hospitals pursuing aggressive cost-cutting while 80% simultaneously plan service line expansion, creating demand for technologies that do more with existing infrastructure rather than requiring expensive facility buildouts or staff additions^[4].

Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just announced a partnership with Nisg̱a'a Valley Health Authority that establishes a global model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration centers on Ventripoint's VMS+ system, which transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy. This technology enables precise cardiac assessments at the point of care, reducing costs and eliminating the need for time-consuming MRI scans.

The model follows a hub-and-spoke design where a central hub with advanced cardiac capabilities supports connected sites in smaller, remote, and Indigenous communities. Local healthcare providers can acquire ultrasound scans and transmit them digitally to specialists at the hub for rapid interpretation. The Nisg̱a'a Valley Health Authority will serve as the first remote site in this network, linked to a regional center with tertiary and quaternary care capabilities.

"Through our collaboration with the Nisg̱a'a Nation, we are creating a scalable model of heart care that can extend from the Arctic to the Amazon, ensuring that everyone, regardless of geography, has access to advanced diagnostics," said Hugh MacNaught, CEO of Ventripoint.

Future phases are intended to include additional First Nations communities across Canada, Arctic regions, and rural communities worldwide, including areas in the Amazon, Africa, and India where MRI access is limited. The model delivers advanced cardiac imaging directly to patients without the need for long-distance travel, high costs, or extended wait times.

"Partnering with Ventripoint allows us to explore innovative tools that support more accurate diagnoses, faster treatment decisions, and truly patient-centred care right here at home," said Corinne McKay, CEO of Nisga'a Valley Health Authority. "For NVHA, this collaboration is about more than technology. It is about advancing health sovereignty for the Nisg̱a'a Nation and strengthening our ability to serve our people with excellence, compassion, and cultural integrity."

The company also recently appointed David Swetlow as Chief Financial Officer in October. Swetlow brings over 15 years of senior management experience from high-growth medical technology companies, including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a refreshed commercial strategy designed to drive market adoption and revenue growth across international markets.

In late October, Ventripoint announced a collaboration with Providence Health Care Ventures to validate VMS+ at St. Paul's Hospital in Vancouver. The study will evaluate whether AI-enhanced echocardiography can reduce demand for cardiac MRI scans at one of Western Canada's leading cardiac programs. Implementation is expected to begin in early 2026.

The company also issued a corporate update detailing its shift toward a Device-as-a-Service subscription model. Management believes this approach will shorten sales cycles and build recurring revenue. The update noted that qualified leads from Europe and North America are increasing, and that Ventripoint's European distributor AngioPro has recommitted to the company and invested additional capital.

CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint

In other industry developments and happenings in the market include:

Heartflow, Inc. (NASDAQ: HTFL) presented late-breaking data from the FISH&CHIPS Study at AHA Scientific Sessions 2025, validating its AI-powered Plaque Analysis platform in nearly 8,000 symptomatic patients and demonstrating patients in the highest total plaque volume stage experienced more than a 5x greater risk of major cardiovascular events compared with the lowest stage. The retrospective analysis represents the largest validation to date of Heartflow's Plaque Staging framework, with associations remaining significant after adjustment for coronary stenosis and cardiovascular risk factors over a median 3.3 years of follow-up.

"We are demonstrating how AI-powered Heartflow Plaque Analysis with Heartflow Plaque Staging can fundamentally change the way we manage CAD," said Campbell Rogers, Chief Medical Officer at Heartflow. "These latest findings show that by embedding plaque insights directly into the diagnostic pathway, we can help physicians make more confident decisions to guide personalized and precise treatment for their patients."

Heartflow's platform has been adopted by more than 1,400 institutions globally and has redefined care for nearly 500,000 patients worldwide, backed by ACC/AHA guidelines and over 600 peer-reviewed publications. The company's proprietary data pipeline built from more than 110 million annotated CTA images powers advanced AI models delivering coronary CTA image acceptance rates exceeding 96 percent, with DECIDE Registry data showing management changes guided by Plaque Staging resulted in an expected 15 percent decrease in cardiac event risk.

CeriBell, Inc. (NASDAQ: CBLL) received FDA 510(k) clearance for its next-generation Clarity algorithm to detect electrographic seizures in newborns pre-term and older, becoming the first and only FDA-cleared AI-powered seizure detection system spanning all patient ages from pre-term neonates through adults. The clearance addresses a critical unmet need in neonatal care, where approximately 9% of NICU patients are diagnosed with seizures but research suggests up to 90% go undetected without EEG monitoring, and high-risk newborns seizing for more than 13 minutes per hour face an 8-fold increased risk of mortality and long-term disability.

"Seizures are the most common neurological emergency in newborns, and protecting these fragile brains is essential to their long-term development and well-being," said Jane Chao, Ph.D., co-founder and CEO of Ceribell. "This FDA clearance enables us to further expand availability of Ceribell's rapid, AI-powered neurological monitoring technology and serve more patients in need. Every newborn deserves timely and accessible seizure detection, without the delays and transfers that too often put outcomes at risk."

The clearance was supported by EEG data from more than 700 patients, representing the largest known validation dataset ever used for a neonatal seizure detection system. Ceribell's point-of-care EEG system combines proprietary algorithms with purpose-built hardware, including a headcap specifically optimized for neonatal patients, enabling real-time detection of non-convulsive seizures to support rapid diagnosis and treatment in intensive care units and emergency rooms across the U.S.

Medtronic plc (NYSE: MDT) and Abbott Laboratories (NYSE: ABT) have begun broad U.S. commercial launch of the MiniMed 780G system integrated with Abbott's Instinct sensor, marking a major milestone in AI-powered diabetes management as the system automates insulin adjustments every five minutes based on real-time glucose data. The Instinct sensor, based on Abbott's most advanced CGM technology, features the world's smallest and thinnest integrated continuous glucose monitor with up to 15 days of wear time, now shipping to customers nationwide following FDA clearance earlier this year.

"This milestone marks an important next step in our work to bring the proven clinical outcomes of our MiniMed 780G system to more people living with diabetes," said Que Dallara, EVP and president of Medtronic Diabetes. "With this launch, we're expanding a smart dosing ecosystem built for choice, so every person can find a solution that fits their life. We exist to make life with diabetes easier and more predictable, so people living with diabetes can enjoy greater freedom and better health every day."

The launch expands Medtronic's sensor portfolio alongside the recently launched Simplera Sync sensor and Guardian 4 sensor, with the company's diabetes business committed to designing the future of diabetes management through next-generation sensors, intelligent dosing systems, and data science and AI. Early customer pilot program feedback has shown improved time in range for patients, with the algorithm-driven system helping people with diabetes spend less time managing their condition through automated insulin delivery that adjusts to glucose readings in real time.

Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint

CONTACT:

USA NEWS GROUP 

info@usanewsgroup.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

1.   https://www.mdpi.com/2075-4418/15/22/2845

2.   https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/

3.   https://www.medicaleconomics.com/view/how-different-sectors-of-the-health-care-industry-can-overcome-challenges-in-2025

4.   https://www.alithya.com/en/insights/blog-posts/2025-healthcare-system-priorities-and-pressures-key-insights 

Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-diagnostics-hit-critical-mass-as-hospitals-race-to-cut-costs-302640231.html

Equity Insider News Commentary

Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- Equity Insider News Commentary – Amid the wave of new AI-powered innovations in healthcare, so far ambient scribes have emerged as the breakout use case. As the range of AI uses for the healthcare sector continues to grow, experts are analyzing the potential ROI on their implementation, and how much they'll benefit early adopters. Healthcare leaders are already seeing improvements, such as slashed clinician workloads from voice AI, and the adoption of AI agents to increase efficiency and smarter care delivery. For investors looking for remaining early-mover advantages, there have been several publicly-traded companies with recent developments worthy of capturing their attention, including Avant Technologies, Inc. (OTCQB: AVAI), Spectral AI, Inc. (NASDAQ: MDAI), Palantir Technologies (NADSAQ: PLTR), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and CeriBell, Inc. (NASDAQ: CBLL).

Investor interest in private companies is surging, as venture capital continues to pour into the AI-in-healthcare space. In Q1 alone, AI firms accounted for more than half of all digital health funding. Recent raises include $45 million for Ellipsis Health and $28 million for Autonomize AI, both targeting next-gen clinical intelligence. From diagnostics to drug discovery, the pace of innovation is accelerating — and many of these rollouts are now catching the attention of retail investors.

One example is the rollout of AI-powered screenings for diabetic retinopathy now underway across Costa Rica, Nicaragua, and Panama. Avant Technologies, Inc. (OTCQB: AVAI) and joint-venture partner Ainnova Tech have begun offering free Vision AI scans inside Grupo Dökka's Fischel and La Bomba pharmacy chains. The fast, non-invasive test detects early retinal changes—often before symptoms appear—and delivers secure results within minutes. By embedding the service in retail pharmacies and preparing for a parallel launch in Mexico, the partners are bringing care closer to patients while generating real-world data to support broader commercialization.

"As we begin similar initiatives in Mexico, our goal is to close the patient care loop with timely treatment, connecting every step of the journey," said Vinicio Vargas, CEO of Ainnova Tech and board member of Ai-nova Acquisition Corp. "We are integrating pharma, retail, ophthalmologists, and our technology into a unified experience, all driven by one incentive, the well-being of the diabetic patient."

The rollout also gives Avant a timely proof point as it moves to consolidate Vision AI under one roof. Earlier this month, the company signed a non-binding letter of intent to acquire 100% of Ainnova Tech—bringing leadership, data, and intellectual property together ahead of a scheduled FDA pre-submission meeting in July. Folding the joint venture into a single public entity would remove the current holding-company structure, streamlining everything from regulatory filings to revenue recognition. Management sees the unified cap table as a potential draw for both investors and strategic partners.

While the legal teams work through due diligence, engineers are finalizing a low-cost, automated retinal camera built to work seamlessly with the Vision AI platform. Legacy fundus cameras can run into the tens of thousands and typically require skilled operators. Avant's prototype is fully automated, cloud-connected, and designed for a fraction of the cost. If performance holds up to internal testing, the system could enable large-scale diabetic screenings in clinics and low-resource settings—without the need for additional specialist staff.

Vision AI is also expanding beyond diabetic eye disease. A patented dementia-risk module—pairing a five-minute blood test with AI pattern recognition—is now in validation, while cardiovascular-risk analytics are advancing through pilot studies across Latin America. Because every new use case plugs into the same software backbone, Avant looks more like a scalable platform than a single-product company.

On the financial side, the planned merger would fold all outstanding Ainnova shares into Avant's public float, avoiding cash dilution and fully aligning the combined team's incentives. Management says any future fund-raising would be aimed at three priorities: completing the automated camera, widening pharmacy deployments, and supporting U.S. regulatory milestones.

Taken together, the pharmacy roll-out, planned Ainnova acquisition, and imminent camera launch signal a turning point for Avant. What began as an AI incubator is fast becoming a full-stack diagnostics company, complete with proprietary hardware, an expanding library of predictive algorithms, and retail-level distribution partners. If execution matches vision, Vision AI could cut referral delays, open earlier treatment windows, and give resource-strained health systems specialist-grade insight at primary-care prices—turning headline-grabbing tech into tangible patient benefits.

CONTINUED... Read this and more news for Avant Technologies at: 

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

Spectral AI, Inc. (NASDAQ: MDAI) continues to advance its DeepView® System, an AI-powered wound imaging platform designed to assess burn healing potential without invasive biopsies.

The company's technology was recently spotlighted at the British Burn Association Conference, where new clinical data from UK hospitals showed DeepView® improved detection rates from 61% to 89%.

"UK investigators shared valuable advancements with DeepView during the BBA meeting," said Dr. Jeffrey Carter, M.D., Louisiana State University Health Science Center. "Their early clinical experience demonstrated promising sensitivity and specificity results, along with a positive patient experience and a comprehensive evaluation of TBSA (Total Body Surface Area) calculation methods."

The system aims to accelerate triage decisions and reduce treatment errors in both civilian and military burn care.

Palantir Technologies (NADSAQ: PLTR) has entered into a strategic partnership with TeleTracking Technologies to deliver AI-powered operational insights to hospitals and health systems. The collaboration combines TeleTracking's Operations IQ platform with Palantir's Foundry and AIP, offering real-time visibility into staffing, capacity, and patient flow.

"This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of-where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care," said Alex Karp, CEO at Palantir.

According to both companies, the platform will unlock real-time visibility across health systems while easing the load on overburdened staff. Executives describe it as a foundational shift toward AI-native operations in healthcare.

GE HealthCare Technologies Inc. (NASDAQ: GEHC) has partnered with Stanford Medicine to advance total-body PET/CT technology that incorporates AI into every stage of the imaging process. The system delivers high-resolution, full-body scans in a fraction of the time, while reducing radiation dose for patients.

"Our total body PET/CT technology represents the next chapter in our enduring commitment to advancing medical imaging," said Jean-Luc Procaccini, President & CEO, Molecular Imaging and Computed Tomography, GE HealthCare. "We're proud to collaborate with world-class institutions to explore new clinical frontiers in oncology and beyond. Together with our MIM software solutions, we're designing flexible, AI-enhanced tools that not only aim to enhance diagnostic confidence and operational efficiency but also help clinicians deliver more precise, personalized care that can truly improve patient outcomes."

Key to the innovation is a deep-learning reconstruction engine that enhances detail and enables exploratory insights across oncology, cardiology, and neurology. GE HealthCare sees the platform as a foundation for identifying novel biomarkers, guiding treatment, and supporting large-scale clinical research.

CeriBell, Inc. (NASDAQ: CBLL) is gaining momentum with its Rapid Response EEG system, which uses artificial intelligence to detect non-convulsive seizures in critical care settings. The company reported over 54,000 patients monitored in Q1 2025 alone, with 70% of seizures identified outside neurology departments—highlighting its utility in high-pressure environments.

"We are pleased with our strong start to the year as we further expanded our account base while benefiting from accelerated adoption of the Ceribell system," said co-founder and CEO Jane Chao, Ph.D. "We also look forward to offering our pediatric Clarity algorithm to customers while continuing to invest in our product development pipeline with the goal of ultimately making EEG a new vital sign."

With multiple AI modules, including seizure triage and brain function trending, Ceribell is becoming a key player in real-time neurological diagnostics.

Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/

CONTACT:

Equity Insider

info@equity-insider.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Video - https://www.youtube.com/watch?v=MFa8N3ybVaI

Logo - https://mma.prnewswire.com/media/2644233/5380279/Equity_Insider_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ai-tools-that-talk-scan-and-save-lives-are-reshaping-the-investment-landscape-302487108.html